Mycamine (Micafungin Sodium)

Micafungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, preventing the synthesis of β‑(1,3)‑D‑glucan, an essential structural component of the fungal cell wall. Without a functional cell wall, the fungus becomes osmotically unstable and dies, while human cells are unaffected because they lack this pathway.

The specific dose and duration of Mycamine therapy are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals should follow local guidelines and product labeling.

Safety data for micafungin in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it should only be used if the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To request Mycamine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mycamine belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to cell‑membrane sterols. Echinocandins like micafungin are often preferred for invasive Candida infections due to their fungicidal activity and lower drug‑interaction potential.

Mycamine should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain ensures drug stability and efficacy until the point of administration.

Mycamine is supplied as a sterile powder for injection and is reconstituted with the appropriate diluent. It is administered intravenously over a specified infusion period, typically under the supervision of a qualified healthcare professional in a clinical setting.

Serious risks include hepatotoxicity, severe hypersensitivity reactions such as anaphylaxis, and significant hypotension during infusion. Patients should be monitored for signs of liver injury, allergic response, and blood pressure changes throughout treatment.

Mycamine is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, and it should be avoided in neonates unless the benefit outweighs the risk.